Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
National Lung Matrix Trial in non-small cell lung cancer
ISRCTN38344105Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Mar 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, open-label trial of fexagratinib, vistusertib, palbociclib, crizotinib, selumetinib and 6 more in non-small cell lung cancer (NSCLC) (10 arms), sponsored by University of Birmingham. Primary endpoints: Objective response, Durable clinical benefit and 1 more. Started Mar 2015; status: completed.
02
Drugs
fexagratinibvistusertibpalbociclibcrizotinibselumetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ISRCTN38344105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN38344105.